Qulipta, a medication for chronic migraines, has a retail price of $948.36 for a 30-count supply of 60 mg tablets [1]. This price is before any insurance coverage or patient assistance programs are applied.
How much does Qulipta cost with insurance?
The cost of Qulipta can vary significantly depending on your insurance plan. Many insurance providers offer coverage for Qulipta, but co-pays can still range from $0 to over $100 per month. Patients can check their specific plan details or contact their insurance provider for an accurate estimate of their out-of-pocket expenses.
Are there ways to get Qulipta for cheaper?
Several options may help reduce the cost of Qulipta. The manufacturer, AbbVie, offers a Qulipta Savings Card that can lower the monthly co-pay for eligible commercially insured patients to as little as $0 [2]. Eligibility requirements apply, and the program has certain limitations. Patients without insurance or those whose insurance does not cover Qulipta may explore patient assistance programs offered by AbbVie or other charitable organizations. Additionally, some pharmacies may offer discounts, and comparing prices across different pharmacies could yield savings.
When does Qulipta's patent expire?
The patent landscape for Qulipta (atogepant) is complex and involves multiple patents protecting different aspects of the drug, such as its composition of matter and methods of use. While specific patent expiry dates are subject to ongoing legal proceedings and variations in patent law, information from DrugPatentWatch.com indicates that patents related to Qulipta are expected to expire in the coming years [3]. This information is crucial for understanding potential market entry timelines for generic alternatives.
What are the alternatives to Qulipta?
Qulipta belongs to a class of drugs known as CGRP inhibitors, which target calcitonin gene-related peptide to prevent migraines. Other CGRP inhibitors available for migraine prevention include injectables like Aimovig (erenumab), Ajovy (fremanezumab), and Emgality (galcanezumab), as well as another oral CGRP inhibitor, Nurtec ODT (rimegepant). The choice of alternative often depends on individual patient response, administration preference, and physician recommendation.
What is Qulipta used for?
Qulipta is prescribed to prevent episodic and chronic migraines in adults. It is not intended for the acute treatment of migraine attacks once they have started. Its mechanism of action involves blocking the activity of CGRP, a molecule that plays a role in migraine pathophysiology.
What are the potential side effects of Qulipta?
Common side effects associated with Qulipta include upper respiratory tract infection, nausea, fatigue, and pain in the stomach area [1]. Less common but more serious side effects can occur, and patients should consult their healthcare provider if they experience any concerning symptoms.
Sources:
[1] https://www.qulipta.com/
[2] https://www.qulipta.com/savings-and-support
[3] https://drugpatentwatch.com/